Manufacturer of Testim Gel Cleared of Liability in Bellwether Trial

In the third federal bellwether trial over the side effects of testosterone replacement therapy, and the first case involving use of Testim gel, a federal jury has found that the drug manufacturer is not responsible for a heart attack suffered by a Tennessee man.

The case is part of a series of planned “bellwether” cases, designed to help gauge how juries may respond to similar evidence and testimony that will be presented throughout more than 6,000 other Testim lawsuits, Androgel lawsuitsAxiron lawsuits and other claims brought by individuals who suffered a heart attack, stroke, blood clot or other injuries after using the controversial drugs.

The bellwether trials began over the summer against AbbVie, the makers of Androgel, which is the most widely used testosterone replacement therapy. Additional cases are scheduled in the coming months against Auxilium, the makers of Testim, and Eli Lilly, the makers of Axiron.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

In July 2017, the first lawsuit to reach a jury resulted in a $150 million punitive damage award against the makers of Androgel, indicating that AbbVie should be punished for their reckless disregard for the safety of users of their testosterone drug.

Last month, a second Androgel trial ended in another massive verdict against AbbVie, with $140 million in compensatory and punitive damages awarded to one plaintiff.

The latest trial involved a lawsuit filed by Steve Holtsclaw, who claimed that he suffered a heart attack in 2014, due to the side effects of Testim. However, Auxilium argued at trial that Holtsclaw had a number of medical conditions that put him at risk of heart disease, and convinced the jury that he had not established that his heart attack was caused by Testim.

The next case is slated to begin on January 8, involving another complaint against AbbVie over the side effects of AndroGel. That will be followed by a case against Eli Lilly, the makers of Axiron, which is expected to begin on January 29.

Although the outcomes of these bellwether trials are not binding on other plaintiffs, they are being closely watched by parties involved, as they may influence eventual negotiations to reach testosterone injury settlements, which would avoid the need for thousands of individual cases to be set for trial in courts nationwide over the coming years.

Image Credit: |

0 Comments

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Court Allows Suboxone Tooth Decay Lawsuits To Be Filed in Bundled Complaint by June 14, 2024
Court Allows Suboxone Tooth Decay Lawsuits To Be Filed in Bundled Complaint by June 14, 2024 (Posted 2 days ago)

A federal judge is allowing plaintiffs to file large numbers of Suboxone tooth decay lawsuits in one bundled complaint, to meet a potential two-year statute of limitations deadline, with the ability to flesh those claims out in more detail at a later date.